In particular, patients with early-stage (I and II) ovarian tumors expressing high levels of SMARCE1 showed significantly lower probability of survival (n = 179, HR = 1.19, P =0.019) (Fig. 2 C, Top). The gene discussed is SMARCE1; the disease is ovarian neoplasm.